The US Food and Drug Administration today approved a pill version of the blockbuster anti-obesity drug Wegovy. Made by Novo Nordisk, the pill is taken once a day. The company’s original version of Wegovy is a weekly injection. Both drugs contain the same active ingredient, semaglutide.

“This allows patients with obesity who want to lose weight to have a choice between a once weekly injection or a daily tablet,” says Martin Holst Lange, chief scientific officer at Novo Nordisk.

With the soaring popularity of injectable GLP-1 drugs for weight loss, Novo Nordisk and other pharmaceutical companies have been racing to make effective pill versions that could be preferable for some patients. These drugs mimic a naturally occurring hormone in the body that acts on the brain and gut to promote a feeling of fullness.

In clinical trial results published in the New England Journal of Medicine, participants who took the pill achieved an average weight loss of 13.6 percent by 64 weeks. Nearly 30 percent of people lost 20 percent or more of their weight. The study also showed improvements in cardiovascular disease risk and physical activity levels similar to the injectable version.

While pills can sometimes be a more convenient option, patients may not always take them as prescribed, making them less effective. The clinical trial investigators estimated that in an ideal scenario where participants take the pill every day as prescribed, weight loss would be 16.6 percent—which is similar to results seen with injectable Wegovy.

Novo Nordisk first won approval for an oral semaglutide, sold under the brand name Rybelsus, in 2019 to treat type 2 diabetes. That drug has never been approved for obesity and is not as effective for weight loss as newer GLP-1 medications. The Wegovy pill is essentially a higher-dose version of Rybselsus.

“The efficacy for the obesity pill at the end of the day is driven by dose. Higher doses are required to achieve full weight-loss potential for obesity,” Lange says. The Wegovy pill is 25 milligrams while Rybelsus is 14 milligrams.

The most common side effects of oral Wegovy include nausea and vomiting, which are also side effects of the injectable version.

Novo has not disclosed the exact timeline for the drug’s launch, but Lange says it will be available sometime in the first few months of 2026. Production of the medication is already underway at Novo Nordisk’s US manufacturing sites, and the company expects to have enough of the drug to meet US demand.

Over the weekend, the Justice Department released three new data sets comprising files related to Jeffrey Epstein. The DOJ had previously released nearly 4,000 documents prior to the Friday midnight deadline required by the Epstein Files Transparency Act.

As with Friday’s release, the new tranche appears to contain hundreds of photographs, along with various court records pertaining to Epstein and his associates. The first of the additional datasets, Data Set 5, is photos of hard drives and physical folders, as well as chain-of-custody forms. Data Set 6 appears to mostly be grand jury materials from cases out of the Southern District of New York against Epstein and his coconspirator, Ghislaine Maxwell. Data Set 7 includes more grand jury materials from those cases, as well as materials from a separate 2007 Florida grand jury.

Data Set 7 also includes an out-of-order transcript between R. Alexander Acosta and the DOJ’s Office of Professional Responsibility from 2019. According to the transcript, the OPR was investigating whether attorneys in the Southern District of Florida US Attorney’s Office committed professional misconduct by entering into a non-prosecution agreement with Epstein, who was being investigated by state law enforcement on sexual battery charges. Acosta was the head of the office when the agreement was signed.

Leading up to the deadline to release materials, the DOJ made three separate requests to unseal grand jury materials. Those requests were granted earlier this month.

The initial release of the Epstein files was met with protest, particularly by Epstein victims and Democratic lawmakers. “The public received a fraction of the files, and what we received was riddled with abnormal and extreme redactions with no explanation,” wrote a group of 19 women who had survived abuse from Epstein and Maxwell in a statement posted on social media. Senator Chuck Schumer said Monday that he would force a vote that would allow the Senate to sue the Trump administration for a full release of the Epstein files.

Along with the release of the new batch of files over the weekend, the Justice Department also removed at least 16 files from its initial offering, including a photograph that depicted Donald Trump. The DOJ later restored that photograph, saying in a statement on X that it had initially been flagged “for potential further action to protect victims.” The post went on to say that “after the review, it was determined there is no evidence that any Epstein victims are depicted in the photograph, and it has been reposted without any alteration or redaction.”

The Justice Department acknowledged in a fact sheet on Sunday that it has “hundreds of thousands of pages of material to release,” claiming that it has more than 200 lawyers reviewing files prior to release.